Verrica Pharmaceuticals Inc.
9 clinical trials · Sponsor
◉ Watch Verrica Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) (NCT07457918) | Verrica Pharmaceuticals Inc. | 2026-03-11 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) (NCT07246590) | Verrica Pharmaceuticals Inc. | 2025-12-17 |
| Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma (NCT05188729) | Verrica Pharmaceuticals Inc. | 2022-02-01 |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts (NCT03981822) | Verrica Pharmaceuticals Inc. | 2019-06-25 |
| Cantharidin and Occlusion in Verruca Epithelium (NCT03487549) | Verrica Pharmaceuticals Inc. | 2018-03-27 |
| Cantharidin Application in Molluscum Patients-1 (NCT03377790) | Verrica Pharmaceuticals Inc. | 2018-03-21 |
| Cantharidin Application in Molluscum Patients (NCT03377803) | Verrica Pharmaceuticals Inc. | 2018-02-14 |
Track Verrica Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.